tab glevo 250
The clinical usefulness of levofloxacin, an optical active isomer of ofloxacin, was investigated on uro-genital infections. Patients who were treated with the drug included 2 with complicated urinary tract infections (UTI), 29 with chronic prostatitis and 3 with chronic non-chlamydial epididymitis. Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12.0 +/- 0.5 days). In 2 cases of chronic UTI, infected by P. aeruginosa in one case and P. stutzeri in another case, the isolates were eradicated, and the clinical efficacy was moderate or excellent. For evaluating the effectiveness on chronic prostatitis, the patients were divided into 2 groups; group I (G-I) was chronic bacterial (number of isolates including GNR or E. faecalis, greater than or equal to 10(4) ml) and group II (G-II) was chronic non-bacterial prostatitis (number of isolates including GPC less than or equal to 10(3)/ml). A complete bacteriological response was obtained in all 7 cases, classified in G-I, but in 20 of the 27 isolates, (74.1%) in G-II. In 3 cases of chronic non-chlamydial epididymitis, the response was moderate. In safety profile, there were slight elevations in the laboratory values of glutamic oxaloacetic transaminase (GOT), and glutamic pyruvic transaminase (GPT) in one case, and that of GOT in another case. As for side effects, a 69-year-old male complained of dizziness, and anorexia after 10 days on the drug, but recovered 2 days after discontinuance of the drug.
tab glevo 750
Hospitals are advised to measure antibiotic use and monitor its relationship to resistance. The World Health Organization's recommended metric is the defined daily dose (DDD). An alternative measure is the number of days of therapy (DOT). The purpose of this study was to contrast these measures.
A total of 284 patients who failed prior H. pylori eradication were randomized to receive 14-day regimens containing lansoprazole 30 mg twice a day (b.i.d.), bismuth subcitrate 240 mg b.i.d., and either amoxcillin, 1 g b.i.d. and levofloxacin 500 mg once daily (qd) (levofloxacin/bismuth therapy) or metronidazole 400 mg four times daily (q.i.d.) and tetracycline, 500 mg q.i.d. (BMT quadruple therapy). Endoscopy and culture were performed before treatment. Antimicrobial susceptibility was by agar dilution. H. pylori status was determined 6 weeks after the end of therapy using a (13)C-urea breath test.
glevo 750 mg
Many hospitalized patients continue to receive intravenous medications longer than necessary. Earlier conversion from the intravenous to the oral route could increase patient safety and comfort, reduce costs, and facilitate earlier discharge from the hospital without compromising clinical care. We examined the effect of a computer-based intervention to prompt physicians to switch appropriate patients from intravenous to oral medications.
glevo pod tablet
A simple and rapid HPLC-UV method has been developed for determination of levofloxacin in human plasma. Chromatographic separation was performed on a Kromasil C18 column with the mobile phase consisting of acetonitrile, water, phosphoric acid and triethylamine (14:86:0.6:0.3, v/v/v/v) and flow rate was 1.0 mL/min. The method used ultraviolet detection set at a wavelength of 294 nm. The standard curves were linear over concentration range of 0.05-5.0 μg/mL (r > 0.99). The method was simple, rapid, precise, accurate and suitable for routine bioequivalence study. The method was successfully applied to the bioequivalence study of two different levofloxacin hydrochloride capsules in Chinese healthy volunteers.
t glevo 500 mg
The infection control strategies implemented proved to be effective in achieving outbreak control and in maintaining the baseline C. difficile incidence rate following it. The reported C. difficile outbreak was associated with the prescription of broad-spectrum antibiotics and a medical history of diabetes.
tab glevo pod
Introducción: las causas implicadas en el aumento de incidencia de úlcera gástrica tras el bypass en Y de Roux no son completamente conocidas. El tratamiento de la infección por HP se recomienda antes de la cirugía en países cuya prevalencia sea elevada, como el caso de España, de cara a disminuir dicha complicación. Sin embargo, las pautas actuales de tratamiento pueden no ser adecuadas dados los elevados índices de resistencia. Pacientes y métodos: análisis retrospectivo de 243 pacientes operados de bypass en Y de Roux. De ellos, 111 pacientes (45%) presentaban infección por HP. Objetivo principal: comparación de la eficacia de dos terapias de erradicación de la infección por HP. Resultados: 70 pacientes recibieron OCA( Omeprazol 20 mg/12 h, Claritromicina 500 mg/12 h y Amoxicilina 1 g/12h durante 10 días), mientras que 41 pacientes recibieron OLA (Omeprazol 20 mg/12 h, Levofloxacino 500 mg/12 h y Amoxicilina 1 g/12 h durante 10 días). En 56/70 pacientes (80%) que recibieron OCA HP fue erradicado, comparado con 37/41 (91%) del grupo que recibió OLA como primera terapia (p = 0,283). La terapia con OLA usada de segunda línea fue eficaz en 13/14 pacientes con HP resistente a la terapia OCA. Conclusión: la resistencia de HP a Claritromicina es significativa en nuestra serie de pacientes, siendo la terapia con OLA una alternativa adecuada en las cepas resistentes.